A Study to Examine the Effect of Reconval K1 Cream to Prevent Skin Toxicity From EGFRI

A Phase II Randomized, Double Blind, Placebo Study to Evaluate the Efficacy of Vitamin K1 Cream Treatment Compared to Placebo for the Prevention of Papulo-pustular Rash in Metastatic Colorectal Patients Receiving First Line EGFRI Treatment.

Vitamin K1 cream may prevent papulopustular rash induced by EGFRI given to metastatic colorectal cancer patients.

This study will prospectively accrue metastatic colorectal patients receiving EGFRI and treat with reconval cream half face versus placebo cream half face to study whether Vitamin k1 cream can prevent the typical skin eruption caused by EGFRI.

Inclusion Criteria:

• metastatic colon cancer patients
• male or female
• age> 18
• treated EGFRI

Exclusion Criteria:

• prior treatment with EGFRI